Suomi -
suomi -
Fimea (Suomen lääkevirasto)
digoxin orion semi 0.125 mg tabletti
aspen pharma trading limited - digoxin - tabletti - 0.125 mg - digoksiini
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
digoxin orion 0.25 mg tabletti
aspen pharma trading limited - digoxin - tabletti - 0.25 mg - digoksiini
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
furosemide accord 10 mg/ml injektio-/infuusioneste, liuos
accord healthcare b.v. - furosemide - injektio-/infuusioneste, liuos - 10 mg/ml - furosemidi
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
furosemide accord 10 mg/ml injektio-/infuusioneste, liuos
accord healthcare b.v. - furosemide - injektio-/infuusioneste, liuos - 10 mg/ml - furosemidi
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
desirett 75 mikrog tabletti, kalvopäällysteinen
exeltis healthcare s.l. - desogestrel - tabletti, kalvopäällysteinen - 75 mikrog - desogestreeli
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
atazanavir accord 200 mg kapseli, kova
accord healthcare b.v. - atazanavir sulphate - kapseli, kova - 200 mg - atatsanaviiri
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
atazanavir accord 300 mg kapseli, kova
accord healthcare b.v. - atazanavir sulphate - kapseli, kova - 300 mg - atatsanaviiri
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
bisolaclar 600 mg poretabletti
opella healthcare france sas - acetylcysteine - poretabletti - 600 mg - asetyylikysteiini
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiset aineet - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
jakavi
novartis europharm limited - ruxolitinibi (fosfaatteina) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiset aineet - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polysytemia vera (pv)jakavi on tarkoitettu aikuisille potilaille, joilla on polysytemia vera, jotka ovat resistenttejä tai intolerantteja ja hydroksiurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.